Avelumab Exposure and Merkel Cell Carcinoma: A Review of Mechanisms and Evidence
From General Health Science to Targeted Pharmacovigilance
The legacy of general health and science information dissemination has long served as a foundational pillar for public understanding, guiding individuals from broad wellness principles to specific clinical contexts. Historically, this framework has enabled communities to navigate complex medical landscapes by emphasizing preventive care, routine screenings, and the importance of informed patient-provider dialogue. Within this tradition, the transition from general health awareness to specialized therapeutic considerations represents a natural evolution, particularly as biomedical advancements introduce novel interventions into standard practice. As we pivot toward occupational exposure concerns, it becomes essential to reframe this heritage within the context of workplace safety and pharmacovigilance. The same principles that underpin general health literacy—vigilance, evidence-based reasoning, and proactive risk assessment—now apply to the scrutiny of emerging pharmaceutical agents. In this domain, the focus shifts from population-level health promotion to the specific circumstances under which certain exposures may occur, particularly in professional settings where handling or administration of therapeutic compounds is routine. This transition does not presuppose causation but rather establishes a framework for systematic inquiry, wherein the relationship between exposure and subsequent health outcomes is examined with the same rigor that characterized earlier public health efforts. By grounding occupational concern in the legacy of general health science, we maintain a neutral, academic stance while opening the door to targeted investigation.
Avelumab: Mechanism of Action and Approved Indications
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel Cell Carcinoma: Etiology and Treatment Landscape
Merkel cell carcinoma has a rising incidence and high mortality. Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment of metastatic MCC is the use of anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which in comparison with conventional chemotherapy show better overall response rates and longer duration of responses (https://pubmed.ncbi.nlm.nih.gov/34445385/). Nevertheless, 50% of patients do not respond or develop immune-related adverse events (irAEs) due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, managed with corticosteroids to full resolution while avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/).
Examining the Causation Question: Avelumab as Treatment, Not Cause
Mechanistic pathways linking avelumab to Merkel cell carcinoma are not straightforward, as avelumab is a treatment for MCC rather than a cause. However, the query asks about causation in the context of exposure leading to harm. In this scenario, avelumab exposure is linked to MCC through its role as a therapeutic agent for the disease. The evidence indicates that avelumab is used to treat metastatic MCC, and its mechanism involves PD-L1 inhibition to enhance anti-tumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who are refractory to avelumab, treatment options are limited. A multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). In avelumab-refractory patients, combined ipilimumab plus nivolumab has been used, with three out of five patients responding according to RECIST 1.1 in a small retrospective study (https://pubmed.ncbi.nlm.nih.gov/33439294/).
Risk Context and Clinical Considerations
Risk anchors regarding the adequacy of warnings for avelumab and Merkel cell carcinoma are relevant. The prescribing information for avelumab includes warnings about immune-related adverse events, but the evidence does not specifically address warnings about MCC causation, as avelumab is indicated for MCC treatment. Causation-related considerations for affected patients involve understanding that avelumab exposure is therapeutic, not causative, for MCC. The timeline between exposure and documented harm is typically measured in weeks to months during treatment, as irAEs can occur at any point during therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who develop progressive disease while on avelumab, the timeline reflects treatment failure rather than harm from the drug itself. In summary, avelumab is a PD-L1 inhibitor approved for metastatic MCC, with a mechanism of action that enhances immune response against tumor cells. While it is associated with immune-related adverse events, there is no evidence linking avelumab exposure to the causation of Merkel cell carcinoma. Instead, avelumab is a standard treatment for the disease, and its use is supported by clinical trial data showing objective responses in a subset of patients. For patients who do not respond or experience adverse events, alternative therapies such as combined ipilimumab plus nivolumab may be considered.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It is a PD-L1 inhibitor approved for metastatic MCC based on clinical trials showing objective responses in about one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). The drug works by enhancing the immune system's ability to fight cancer cells.
What are the risks associated with avelumab therapy?
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, these are side effects of treatment, not evidence that the drug causes MCC.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.